These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7088233)

  • 1. Molecular weight distribution, diffusibility and comparability of middle molecular fractions prepared from normal and uremic sera by different fractionation procedures.
    Gróf J; Menyhárt J
    Nephron; 1982; 30(1):60-7. PubMed ID: 7088233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of six uremic middle molecular compounds by high performance liquid chromatography and analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Chu J; Yuan Z; Liu X; Wu Q; Mi H; He B
    Clin Chim Acta; 2001 Sep; 311(2):95-107. PubMed ID: 11566169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of endogenous middle molecules in normal and uremic body fluids.
    Fürst P; Zimmerman L; Bergström J
    Clin Nephrol; 1976 Apr; 3(2):178-88. PubMed ID: 1277595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Many hitherto unknown peptides are principal constituents of uremic "middle molecules".
    Menyhárt J; Gróf J
    Clin Chem; 1981 Oct; 27(10):1712-6. PubMed ID: 7285323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatographic studies of uremic plasma.
    Mamdani BH; Shaykh MM; Evenson MA; Dunea G
    Int J Artif Organs; 1979 Jul; 2(4):187-91. PubMed ID: 88420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of uremic "middle molecular" fractions by gas chromatography, mass spectrometry, isotachophoresis, and liquid chromatography.
    Schoots AC; Mikkers FE; Claessens HA; De Smet R; Van Landschoot N; Ringoir SM
    Clin Chem; 1982 Jan; 28(1):45-9. PubMed ID: 7055936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent substances in uremic and normal serum.
    Shaykh M; Bazilinski N; McCaul DS; Ahmed S; Dubin A; Musiala T; Dunea G
    Clin Chem; 1985 Dec; 31(12):1988-92. PubMed ID: 4064287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of "middle molecules" presenting vitamin B12 molecular size in normal and uremic body fluids (author's transl)].
    Cueille G
    J Chromatogr; 1978 Jul; 146(1):55-65. PubMed ID: 670358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of polymorphonuclear leukocyte membrane fluidity in uremic patients on hemodialysis.
    Masuda M; Komiyama Y; Murakami T; Murata K
    Nephron; 1990; 54(1):36-41. PubMed ID: 2296343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatomedin inhibitor in uremia.
    Phillips LS; Fusco AC; Unterman TG; del Greco F
    J Clin Endocrinol Metab; 1984 Oct; 59(4):764-72. PubMed ID: 6384255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietic inhibitors in uremic serum.
    Freedman MH; Grunberger T; Saunders EF
    Clin Invest Med; 1982; 5(4):237-40. PubMed ID: 7160111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Middle molecules separation from uraemic serum (author's transl)].
    Dall'aglio P; Buzio C; Gardini GP; Migone L
    Ateneo Parmense Acta Biomed; 1975; 46(5):331-44. PubMed ID: 1236694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 19. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid.
    Boumendil-Podevin EF; Podevin RA; Richet G
    J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.